EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging

Chhanda Bose iD, Judit Megyesi, Oleg Karaduta, Sharda P Singh, Sundararaman Swaminathan, Sudhir V Shah

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.13678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Chhanda Bose und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, Iron Chelating Agents, Sarcopenia, Aging. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, VA, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A decline in skeletal muscle mass and function known as skeletal muscle sarcopenia is an inevitable consequence of aging. Sarcopenia is a major cause of decreased muscle strength, physical frailty and increased muscle fatigability, contributing significantly to an increased risk of physical disability and functional dependence among the elderly. There remains a significant need for a novel therapy that can improve sarcopenia and related problems in aging. Iron accumulation, especially catalytic iron (labile iron) through increased oxidative stress, could be one of the contributing factors to sarcopenia. Our study aimed to examine the effect of an iron chelator on age‐related sarcopenia in mice.

Methods

We investigated the effect of iron chelation (deferiprone, DFP) in sarcopenia, using mice with klotho deficiency ( kl/kl ), an established mouse model for aging. Four weeks old Klotho −/− male mice were treated with 25 mg/kg body weight of iron chelator deferiprone in drinking water for 8–14 weeks ( n = 12/group, treated and untreated). At the end of the study, gastrocnemius, quadriceps and bicep muscles were dissected and used for western blot and immunohistochemistry analysis, histopathology and iron staining. Serum total iron, catalytic iron and cytokine ELISAs were performed with established methods.

Results

Treatment with DFP significantly reduced loss of muscle mass in gastrocnemius and quadriceps muscles ( p < 0.0001). Total and catalytic iron content of serum and iron in muscles were significantly (both p < 0.0001) lower in the treated animals. The inhibitory factor of myogenesis, the myostatin protein in gastrocnemius muscles ( p = 0.019) and serum ( p = 0.003) were downregulated after 8 weeks of therapy accompanied by an increased in muscle contractile protein myosin heavy chain (~2.9 folds, p = 0.0004). Treatment decreased inflammation (serum IL6 and TNFα) ( p < 0.0001, p = 0.005), respectively, and elevated insulin‐like growth factor levels ( p = 0.472). This was associated with reduced DNA damage and reduced 8‐hydroxy 2 deoxyguanosine in muscle and HO‐1 protein ( p < 0.001, p = 079), respectively. Significant weight loss ( p < 0.001) and decreased water intake ( p = 0.012) were observed in untreated mice compared to treatment group. Kaplan–Meier survival curves show the median life span of treated mice was 108 days as compared to 63 days for untreated mice ( p = 0.0002).

Conclusions

In summary, our research findings indicate that deferiprone reduced age‐related sarcopenia in the muscles of Klotho −/− mice. Our finding suggests chelation of excess iron could be an effective therapy to counter sarcopenia. However, additional studies are needed to evaluate and determine the efficacy in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalIron Chelating AgentsSarcopeniaAgingGlucuronidaseAnimalsKlotho ProteinsMiceDisease Models, AnimalMaleIronDeferiprone

Stichwörter der Autor:innen

catalytic irondeferiproneklothomyostatinskeletal muscle sarcopenia

Substanzen

Klotho ProteinsIron Chelating AgentsGlucuronidaseIronDeferiprone

Autor:innen und Institutionen

  • Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
  • University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Pharmacology and Neuroscience Department, Texas Tech Health Sciences Center, Lubbock, Texas, USA.
  • Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Internal Medicine Department, Texas Tech Health Sciences Center, Lubbock, Texas, USA.

ORCID-Profile: Chhanda Bose

Förderung

  • BLRD VA
  • VA
  • U.S. Department of Veterans Affairs

Zitieren

APA

Bose, C., Megyesi, J., Karaduta, O., Singh, S. P., Swaminathan, S., & Shah, S. V. (2025). Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13678

Vancouver

Bose C, Megyesi J, Karaduta O, Singh SP, Swaminathan S, Shah SV. Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.13678

BibTeX
@article{Bose2025,
  author = {Bose, Chhanda and Megyesi, Judit and Karaduta, Oleg and Singh, Sharda P and Swaminathan, Sundararaman and Shah, Sudhir V},
  title = {Iron Chelation Prevents Age‐Related Skeletal Muscle Sarcopenia in Klotho Gene Mutant Mice, a Genetic Model of Aging},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.13678}
}
Kostenlos starten →